Literature DB >> 19843679

Elevated cancer mortality in the relatives of patients with pancreatic cancer.

Li Wang1, Kieran A Brune, Kala Visvanathan, Daniel Laheru, Joseph Herman, Christoper Wolfgang, Richard Schulick, John L Cameron, Michael Goggins, Ralph H Hruban, Alison P Klein.   

Abstract

Most inherited cancer syndromes are characterized by the familial clustering of cancers at several organ sites. To determine if cancers, other than pancreatic cancer, cluster in pancreatic cancer kindreds, we examined mortality patterns among the relatives of National Familial Pancreatic Tumor Registry probands. Over 200,000 person-years of follow-up from 8,564 first-degree relatives of probands and 1,007 spouse controls were included in these analyses. We compared mortality rates of National Familial Pancreatic Tumor Registry participants to US population rates using weighed standardized mortality ratios (wSMR). Analyses were stratified by family history of pancreatic cancer (sporadic versus familial), family history of young onset pancreatic cancer (<50 years), and family history score. Cancer mortality was increased in both the relatives of sporadic probands [wSMR 1.55, 95% confidence interval (95% CI) 1.39-1.73] and familial probands (wSMR 1.41, 95% CI 1.26-1.58). Relatives of familial probands had a significantly increased risk of dying from breast (wSMR 1.66, 95% CI 1.15-2.34), ovarian (wSMR 2.05, 95% CI 1.10-3.49), and bile duct cancers (wSMR 2.89, 95% CI 1.04-6.39). Relatives of sporadic probands were at increased risk of dying from bile duct cancer (wSMR 3.01, 95% CI 1.09-6.67). Relatives of young onset probands were at higher risk of dying from cancers of the breast (wSMR 1.98, 95% CI 1.01-3.52), colon (wSMR 2.31, 95% CI 1.30-3.81) and prostate (wSMR 2.31, 95% CI 1.14-4.20). Increased cancer mortality was not observed in the spouse controls. Our results show that relatives of pancreatic cancer patients are at higher risk of developing cancers at other sites and highlight the importance of complete family history in clinical risk assessment.

Entities:  

Mesh:

Year:  2009        PMID: 19843679      PMCID: PMC3190638          DOI: 10.1158/1055-9965.EPI-09-0557

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

1.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Authors:  M Goggins; M Schutte; J Lu; C A Moskaluk; C L Weinstein; G M Petersen; C J Yeo; C E Jackson; H T Lynch; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

2.  A gene for hereditary pancreatitis maps to chromosome 7q35.

Authors:  D C Whitcomb; R A Preston; C E Aston; M J Sossenheimer; P S Barua; Y Zhang; A Wong-Chong; G J White; P G Wood; L K Gates; C Ulrich; S P Martin; J C Post; G D Ehrlich
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

3.  Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers.

Authors:  G H Su; R H Hruban; R K Bansal; G S Bova; D J Tang; M C Shekher; A M Westerman; M M Entius; M Goggins; C J Yeo; S E Kern
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 4.  Risk factors for pancreatic cancer.

Authors:  Albert B Lowenfels; Patrick Maisonneuve
Journal:  J Cell Biochem       Date:  2005-07-01       Impact factor: 4.429

5.  The prevalence of BRCA2 mutations in familial pancreatic cancer.

Authors:  Fergus J Couch; Michele R Johnson; Kari G Rabe; Kieran Brune; Mariza de Andrade; Michael Goggins; Heidi Rothenmund; Steven Gallinger; Alison Klein; Gloria M Petersen; Ralph H Hruban
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-02       Impact factor: 4.254

6.  Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults.

Authors:  P M Lantz; J S House; J M Lepkowski; D R Williams; R P Mero; J Chen
Journal:  JAMA       Date:  1998-06-03       Impact factor: 56.272

7.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

Authors:  Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

Review 8.  Cancer disparities by race/ethnicity and socioeconomic status.

Authors:  Elizabeth Ward; Ahmedin Jemal; Vilma Cokkinides; Gopal K Singh; Cheryll Cardinez; Asma Ghafoor; Michael Thun
Journal:  CA Cancer J Clin       Date:  2004 Mar-Apr       Impact factor: 508.702

9.  BRCA2 germline mutations in familial pancreatic carcinoma.

Authors:  Stephan A Hahn; Bill Greenhalf; Ian Ellis; Mercedes Sina-Frey; Harald Rieder; Birgit Korte; Berthold Gerdes; Ralf Kress; Andreas Ziegler; John A Raeburn; Donata Campra; Robert Grützmann; Helga Rehder; Matthias Rothmund; Wolff Schmiegel; John P Neoptolemos; Detlef K Bartsch
Journal:  J Natl Cancer Inst       Date:  2003-02-05       Impact factor: 13.506

10.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

View more
  30 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

2.  Genetic susceptibility to pancreatic cancer.

Authors:  Alison P Klein
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 3.  Familial pancreatic cancer--status quo.

Authors:  Volker Fendrich; Peter Langer; Detlef K Bartsch
Journal:  Int J Colorectal Dis       Date:  2013-08-16       Impact factor: 2.571

Review 4.  Inherited pancreatic cancer.

Authors:  Fei Chen; Nicholas J Roberts; Alison P Klein
Journal:  Chin Clin Oncol       Date:  2017-12

5.  Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers.

Authors:  Sunil Amin; Russell B McBride; Jennie K Kline; Elana B Mitchel; Aimee L Lucas; Alfred I Neugut; Harold Frucht
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 6.  Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the TTD group.

Authors:  P Pérez Segura; C Guillén Ponce; T Ramón Y Cajal; R Serrano Blanch; E Aranda
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

Review 7.  Update on familial pancreatic cancer.

Authors:  Ralph H Hruban; Marcia I Canto; Michael Goggins; Richard Schulick; Alison P Klein
Journal:  Adv Surg       Date:  2010

Review 8.  Screening and early detection of pancreatic cancer in high risk population.

Authors:  Ming-Chu Chang; Jau-Min Wong; Yu-Ting Chang
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 9.  Identifying people at a high risk of developing pancreatic cancer.

Authors:  Alison P Klein
Journal:  Nat Rev Cancer       Date:  2012-12-06       Impact factor: 60.716

10.  Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study.

Authors:  Erica J Childs; Kari G Chaffee; Steven Gallinger; Sapna Syngal; Ann G Schwartz; Michele L Cote; Melissa L Bondy; Ralph H Hruban; Stephen J Chanock; Robert N Hoover; Charles S Fuchs; David N Rider; Laufey T Amundadottir; Rachael Stolzenberg-Solomon; Brian M Wolpin; Harvey A Risch; Michael G Goggins; Gloria M Petersen; Alison P Klein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-16       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.